Phase 3 Readout~month

Phase 3 Topline: A Phase 3, Randomized, Double-masked, Placebo-controlled, Parallel-group, Multicenter Trial to Evalu

AMGN overview →Track this catalyst
Indication
Thyroid Eye Disease

Other upcoming events for AMGN

Phase 2 StartPhase 2 Start: Open-label, Uncontrolled, Multicenter Trial to Evaluate the Pharmacokinetics, Pharmacodynamics, Safe
Phase 3 ReadoutPhase 3 Topline: A Phase 3, Multicenter, Open-label, Single-arm Study to Assess the Efficacy and Safety of Apremilast
Phase 3 ReadoutPhase 3 Topline: A Randomized, Double-blind Study to Compare the Pharmacokinetics Between ABP 234 and Keytruda® (Pemb
Phase 3 ReadoutPhase 3 Topline: A Phase 3, 52-Week, Multicenter, Randomized, Placebo-controlled, Double-blind Study to Assess the Ef
Phase 3 ReadoutPhase 3 Topline: PROCLAIM: A Phase 3 Randomized Placebo-controlled Double-blind Study of Romiplostim for the Treatmen

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

  • 200 free AI credits / month to run live multi-agent analysis
  • Watchlist, catalyst alerts & the biotech event calendar
  • Full pipeline, financials & FDA data on every company
Start Free
    Phase 3 Topline: A Phase 3, Randomized, Double-masked, Placebo-controlled, Parallel-group, Multicenter Trial to Evalu — AMGN Phase 3 Readout | BioSniper